The effects of chronic, sustained-release moxonidine therapy on clinical and neurohumoral status in patients with heart failure

International Journal of Cardiology

Volumn 75, Issue 2-3, 2000, Pages 167-176

  Dickstein, Kenneth ^a   Manhenke, Cord ^a   Aarsland, Torbjorn ^b   McNay, John ^c   Wiltse, Curtis ^c   Wright, Theressa ^c  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b Hjertelaget Research Foundation   (Norway)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

Heart failure; Moxonidine; Norepinephrine

Indexed keywords

MOXONIDINE; NORADRENALIN;

ADULT; AGED; ARTICLE; ASTHENIA; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; FEMALE; HEART RATE; HUMAN; INDUCED HYPOTENSION; LONG TERM CARE; MALE; NORADRENALIN BLOOD LEVEL; NORADRENALIN RELEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUSTAINED RELEASE PREPARATION; XEROSTOMIA;

BLOOD PRESSURE; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; HEART FAILURE, CONGESTIVE; HEART RATE; HUMANS; IMIDAZOLES; MALE; NOREPINEPHRINE; PLATELET AGGREGATION INHIBITORS; SYMPATHETIC NERVOUS SYSTEM;

EID: 0034664914     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(00)00319-3     Document Type: Article

References (27)

1. Neurohumoral activation in preclinical heart failure: Remodeling and the potential for intervention
2. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure
3. Effects of catecholamines on lactic acid output during progressive working contractions
4. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction
5. 1-imidazoline receptors
6. LY326869, a second generation of centrally acting drugs: An appraisal of clinical experience
7. Modulation of sympathetic outflow by centrally acting antihypertensive drugs
8. The acute hemodynamic and neurohumoral effects of moxonidine, a sympathetic inhibitor, in congestive heart failure
9. Heart rate variability: Standards of measurement, physiological interpretation, and clinical use
10. The pharmacokinetics of moxonidine
11. Prospective study of heart rate variability and mortality in chronic heart failure
12. Direct evidence from intraneuronal recordings for increased central sympathetic outflow in patients with heart failure
13. Norepinephrine spillover to plasma in patients with congestive heart failure: Evidence of increased overall cardiorenal sympathetic nervous activity
14. Oralβ-adrenergic blockade with metoprolot in chronic severe dilated cardiomyopathy
15. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
16. Acute and short-term effects of clonidine in heart failure
17. Effect of sympathoinhibition on exercise performance in patients with heart failure
18. Clonidine in congestive heart failure: A vasodilator with negative inotropic effects
19. Suppressing sympathetic activation in congestive heart failure: A new therapeutic strategy
20. 1 receptor agonist moxonidine in patients with idiopathic dilated cardiomyopathy and heart failure
21. The effects of moxonidine, a novel imidazolidine, on plasma norepinephrine in patients with congestive heart failure
22. Moxonidine improves heart rate variability in patients with heart failure
23. Moxonidine: A review of its pharmacology and therapeutic use in essential hypertension
24. Aspects of tolerability of centrally acting antihypertensive drugs
25. Safety and tolerability of moxonidine in the treatment of hypertension
26. Heart failure 99: The Moxcon story
27. The potential risk of beta-blockade withdrawal in congestive heart failure due to abrupt autonomic changes